Compare DuPont de Nemours Inc (DD) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs Quest Diagnostics Inc — how do they compare? DuPont de Nemours Inc trades at $131.75 (market cap $17.70B), while Quest Diagnostics Inc trades at $230.72 (market cap $25.06B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and DuPont de Nemours Inc pays the higher dividend (1.83%). Which is the better fit depends on your goals — on Pluang, investors hold DuPont de Nemours Inc for 89 Days and Quest Diagnostics Inc for 56 Days on average.
| DD | DGX | |
|---|---|---|
Market Cap | $17.70B | $25.06B |
Volume | 638,303 | 927,361 |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $247.45 |
52-Week Low | $92.49 | $173.49 |
Typical Hold Time | 89 Days | 56 Days |
Enterprise Value | $19.09B | $30.82B |
Dividend Yield | 1.83% | 1.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $132.48, down 0.6% for the day, with neutral technical signals and mixed fundamentals. The company has beaten earnings estimates for three consecutive quarters but shows declining revenue and negative net income for 2025. Recent innovations include digital tools for sugar separation and sustainable Tyvek materials, while facing legal settlements over PFAS contamination.
Outlook remains cautious with analyst consensus favoring Buy (58.5%) but a price target of $95 below current levels. Key opportunities include margin expansion in healthcare and water technologies, while risks involve ongoing litigation costs, uneven construction demand, and profitability challenges despite recent earnings beats.
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
